Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real life studies and meta-analyses.

Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real life studies and meta-analyses. Expert Rev Hematol. 2020 Mar 10;: Authors: Musto P, La Rocca F Abstract Introduction: In the last few years, monoclonal antibodies have rapidly modified therapeutic strategies for treating patients with multiple myeloma.Areas covered: In this review, the most recent literature data regarding indications for which monoclonal antibodies are currently or potentially approved as salvage therapies in relapsed/refractory myeloma will be discussed. In particular, updated results of antibodies directed against CD38 (daratumumab and isatuximab), SLAMF7 (elotuzumab), BCMA (GSK2857916/belantamab mafodotin), and PD-1/PD-1L axis (nivolumab and pembrolizumab) will be discussed in detail.Expert opinion: Monoclonal antibodies represent a very effective therapeutic strategy that will open novel and dynamic treatment scenarios for myeloma patients in the coming years. Optimal positioning and selection of different antibodies that are or will be soon available, appropriate combinations and careful evaluation of possible new toxicities should be considered in the future management of these patients. PMID: 32153224 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research